• Jaguar Health moved all randomized pediatric MVID patients into a single-blind extension of its pivotal crofelemer crossover trial.
• Extension treatment will generate longer-term safety and efficacy support for an NDA filing targeted for mid-2027.
• Prior results were already presented at ESPGHAN 2026, indicating sustained reductions in parenteral support needs with long-term oral crofelemer.
• An independent monitoring committee reviewed the double-blind phase safety profile, clearing continued active treatment during the extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609100900ACCESSWRNAPR_____1218995) on September 10, 2026, and is solely responsible for the information contained therein.